A meeting is set to take place next month where US health officials will reassess a list of peptide drugs that have been a subject of controversy. The Food and Drug Administration has announced the participants in this meeting, which includes doctors and pharmacists. These individuals have financial connections to the industry surrounding these chemicals.

Further information on this development can be found through KPRC 2 Houston, including details on the FDA panel and the peptide drugs in question.